Kornimate/medical-research-clean huggingface dataset:
effect of the diaphragm stretching technique on nonspecific low back pain

Conditions: Nonspecific Low Back Pain

Summary: this study aims to analyze the efficacy of diaphragm stretching technique on symptomatology in young adults with nonspecific low back pain.

nonspecific low back pain occurs when there is an imbalance in the lower back between functional load and the ability to perform daily tasks. it is characterized as such when there is no specific and well-determined diagnosis and there are no structural changes. the diaphragm and abdominal muscles together create a hydraulic effect in the abdominal cavity, which helps stabilize the spine, providing rigidity to the lumbar spine by increasing intra-abdominal pressure. diaphragmatic changes in patients diagnosed with low back pain may contribute to the lack of spinal control activity through several mechanisms. thus, it is concluded that the diaphragm is anatomically related to the lumbar spine, through its muscle fibers. there are articles that relate the topic of low back pain with osteopathic manual treatment, demonstrating that, despite this lack of scientific evidence, the results obtained at a clinical level are favorable. this study aims to evaluate the effectiveness of diaphragm stretching techniques on symptoms experienced by young adults with non-specific low back pain. in this study, the investigators will analyze the effects of the diaphragm stretching technique on the following variables: the sniff nasal inspiratory pressure test (snip test) , visual analogue scale (vas) score, the schober test and measurement of the distance between the fingers and the ground during anterior flexion of the trunk, without flexion of the lower limbs (also known as the finger tip test).

Eligibility criteria:
inclusion criteria: * nonspecific low back pain; * age between 18 and 30. exclusion criteria: * serious cardiovascular and cardiorespiratory causes; * spinal pathologies and injuries to the lumbar spine; * cancer patients; * pacemaker or implant carriers; * pregnant women or volunteers suspected of being pregnant.

Keywords: diaphragm low back pain osteopathy osteopathic medicine stretching technique young adults
potential effect of dialyzer leaching of bpa from the fresenius optiflux 160nr compared to the nipro elisio-15h

Conditions: End Stage Renal Disease

Summary: the aim of the study is to identify hepatic enzyme and estrogen-dependent biochemical changes that occur when dialysis patients are treated with dialyzers known to leach bpa (bisphenol-a) into the blood, such as the commercially available fresenius f160nr, as compared with the same chemical evaluations in patients being treated with the non bpa containing nipro elisio-15h dialyzer. evaluations of patient's chemistries will be obtained prior to and after 2 months of standard dialysis treatments with each dialyzer.

the investigators propose to elucidate any eventual biochemical changes, and in particular, the in vivo estrogenic activity of bpa (bisphenol-a), when bpa is being leached into the circulation by the fresenius 160nr dialyzer as opposed to the same biochemical changes when there is no bpa being leached, as with the non-bpa containing nipro elisio-15h dialyzer. the estrogen dependent biochemical end points in humans include free testosterone, sex hormone binding globulin (shbg) and thyroid binding globulin (tbg).

Eligibility criteria:
inclusion criteria: * male esrd patients 18 years or older * stable on hemodialysis for more than 3 months * stable hematocrit equal to or above 29 % * stable vascular access * stable anticoagulation * no active infection * able to sign informed consent and able to participate in the study * medically stable exclusion criteria: * participation in another study which may interfere with the planned study * active infection * medical conditions which may interfere with the study (unstable cardiac status, chronic liver disease, active hepatitis as defined by elevated liver enzymes) * females (it is expected that potential changes in estrogenic activity that might be seen in patients exposed to bpa will be modest and would be masked by naturally occurring variability of estrogen activity in women at varying stages of gonadal activity (pre, post-menopausal, different points in menstrual cycle, eventual pregnancy, etc). thus, limiting study to adult males will maximize the possibility of detecting any changes in estrogenic activity.)
natural history study of infants with adrenal masses found on prenatal and/or neonatal imaging

Conditions: Adrenocortical Carcinoma; Localized Resectable Neuroblastoma; Precancerous Condition

Summary: this natural history study is collecting health information about infants with adrenal masses found on prenatal and/or neonatal imaging. gathering information over time from imaging and laboratory tests of infants with adrenal masses may help doctors learn more about the disease and plan the best treatment.

primary objective: i. determine whether nonoperative management of infants with adrenal masses found on prenatal and/or neonatal imaging results in a 3-year survival rate of 95%. secondary objectives: i. estimate the percentage of these patients who are spared surgical resection. ii. evaluate the natural history and histology of perinatal adrenal masses. iii. evaluate the tumor biology and histology of prenatal and neonatal neuroblastomas. iv. determine the tumor characteristics that are associated with a need for resection. outline: patients undergo an abdominal ct or mri scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy. after a patient goes off-observation, they will be monitored every six months for two years, and annually thereafter.

Eligibility criteria:
inclusion criteria: * sonographically identified adrenal mass meeting one of the following criteria: * no greater than 16 ml in volume, if solid * no greater than 65 ml if at least 25% cystic and does not cross the midline * disease limited to the adrenal gland * no evidence of positive contralateral or ipsilateral lymph nodes or other spread outside the adrenal gland by ct scan or mri * no evidence of disease outside the adrenal gland by mibg scan * negative for tumor cells by bone marrow biopsy, if performed * no more than 6 months of age on the date the mass is first identified * no prior chemotherapy * no prior abdominal surgery
two dose levels of privigen in pediatric cidp

Conditions: Pediatric Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Summary: a randomized, open-label, prospective, multicenter study designed to investigate 2 dose levels in pediatric subjects 2 to ≤ 17 years of age with confirmed or possible cidp, either previously exposed to ivig treatment or unexposed to ivig treatment


Eligibility criteria:
inclusion criteria: * male or female subjects 2 to ≤ 17 years of age with confirmed or possible cidp. exclusion criteria: * absence of cidp symptoms * history or family history of inherited neuropathy * diagnosed developmental delay or regression * history of thrombotic episode * known or suspected hypersensitivity to privigen * known allergic or other severe reactions to blood products * female subject of childbearing potential either not using or not willing to use a medically reliable method of contraception or not sexually abstinent during the study * pregnant or breastfeeding mother"
clinical decision support system based on non-invasive tele-monitoring of covid-19 patients

Conditions: COVID-19

Summary: the aim of the study is to provide clinical decision support to healthcare professionals using a wearable for non-invasive multimodal monitoring, allowing early detection of disease progression to severe forms, as well as the detection of significant clinical events. for the development of the study, 500 individuals with covid-19 in home confinement will be randomly assigned to form part of the control group, which will be followed conventionally by primary care professionals, or to the experimental group, which will also be provided with the wearable device for non-invasive multimodal monitoring linked to an app for transfering data. furthermore, the patient will be able to interact with the application on three times daily by indicating the symptoms contemplated and answering the decision clinical questions. in this way, alarms can be generated in the presence of symptoms or significant alterations in the parameters monitored by the device, which the health professionals of the primary care teams included in the study will evaluate at the appropriate time, taking the best decision in each case.

as variables to be considered in order to compare the effectiveness of the system against the conventional monitoring protocol, complemented with real-time patient notification of symptoms, certain variables will be collected, such as: baseline variables: * age, sex, date of covid-19 positive diagnosis (pcr or antigen test). * stage of clinical progression of the disease: according to the primary care covid-19 management * information collected in the telephone clinical assessment questionnaire in the home follow-up of the patient with sars-cov-2 infection variables generated by the study follow-up: * vital signs covered by the bakeey e66 smartwatch device: temperature, respiration rate (rr), heart rate (hr) and oxygen saturation (sato2) * clinical symptoms covered by the home app for submission by the patient: cough, fever, chest pain, respiratory distress (dyspnoea), vomiting and diarrhoea.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of sars-cov-2 disease, detected by pcr or antigen test, performed 72 h prior to patient inclusion in the study. * acceptance to sign the informed consent document. * possession of a smartphone or tablet with internet connection. * possession of mental faculties to participate in the study. exclusion criteria: * age below the age of health majority (16 years). * lack of digital skills to use the home app. * cognitive impairment that prevents the patient from participating in the study. * disabling pathology of the upper limb.

Keywords: telemedicine covid-19 wearable device e-health remote monitoring
a phase i/ii study to evaluate uc1010 treatment in premenstrual dysphoric disorder (pmdd)

Conditions: Premenstrual Dysphoric Disorder

Summary: the study is a phase 1/2 study in two parts. in part 1, the primary objective is to assess the pharmacokinetics of uc1010 when administered subcutaneously as a single dose to healthy women. the safety and tolerability of uc1010 is also evaluated in study part 1. in part 2, the primary objective is to assess the pharmacodynamic effect of uc1010 on premenstrual symptoms in women with premenstrual dysphoric disorder (pmdd) when given during the luteal phase of the menstrual cycle. the pharmacodynamic effect is evaluated through the patients' daily ratings of premenstrual symptoms. in both study parts, two active treatment groups are compared to one placebo group.


Eligibility criteria:
inclusion criteria: part 1 -essentially healthy part 2 -have pmdd according to dsm-iv verified in two menstrual cycles exclusion criteria: * steroid hormonal treatment during the previous three months * treatment with psychopharmaceuticals or other treatment for pms * history of or a significant medical condition ongoing * be pregnant or plan a pregnancy within the study period
experiences of genetics patients with visible abnormalities who facilitate teaching in genetics clinics

Conditions: Learning

Summary: this study will describe the experience of patients with visible physical abnormalities in the genetics clinic when they are involved in teaching others about their condition. information from this study may be used to enhance educational experiences in genetics clinics. patients 18 years of age and older with a visible physical anomaly who have been seen by a genetics professional in the past 5 years may be eligible for this study. in a tape-recorded telephone interview, patients are asked about the following: * their experiences when visiting the genetics clinic * the circumstances under which they have been approached to participate in teaching others * their perspective on specific teaching behaviors used in genetic consultations, and how this perspective is affected by their perception of their own visible difference * the benefits and downsides of being involved in teaching others * the circumstances under which they feel comfortable being approached by genetics providers to help teach others about their condition * the conditions or circumstances that make some individual teaching experiences better or worse than others

it is common for genetics patients to facilitate teaching of others during the course of their genetics exam. patient response to serving as a teaching case has been studied only on a limited extent. this study proposes to qualitatively explore the ways in which taking on a teaching role in a genetics clinic is experienced by patients with visible differences. qualitative telephone interviews with approximately 30 genetics patients with visible differences will be conducted. the interviews will be semi-structured and an interview guide will be loosely followed. interviews will be recorded and transcripts of the interviews will be coded for analysis. a typology of common themes will be compiled and reported. information collected through these interviews will improve understanding of the phenomenon of patients in educator roles, relate experiences to patient expectations and will fill a gap in the published literature. it is additionally hoped that results of this study may inform the development of new recommendations to enhance educational experiences in genetics clinics.

Eligibility criteria:
* inclusion criteria: 1. seen in a genetics clinic or by a genetics professional in the past 5 years. 2. self-reported obvious physical difference or deformity. 3. english speaking. exclusion criteria: 1. younger than 18 years. 2. non-visible or absent physical difference of deformity. 3. cognitively-impaired or incompetent.

Keywords: interview genetics
validation of joint-ai in diagnosing pancreatic solid lesions

Conditions: Pancreatic Cancer; Pancreatitis; Pancreatic Neuroendocine Neoplasms (pNETs); Autoimmune Pancreatitis; Solid Pseudopapillary Neoplasm of the Pancreas

Summary: this clinical trial aims to learn if a multimodal artificial intelligence (ai) model can enhance the diagnosis of pancreatic solid lesions. the main questions it aims to answer are: 1. does the ai model enhance the diagnostic performance of endoscopists in diagnosing pancreatic solid lesions? 2. does the addition of interpretability analysis further improve the diagnostic performance of the assisted endoscopists? researchers will compare the diagnostic performance of endoscopists with or without the assistance of the ai model. participants will: 1. their clinical data will be prospectively collected. 2. they will be randomized to the ai-assist group and the conventional diagnosis group.

the investigators have previously developed a multimodal ai model (joint-ai) based on endoscopic ultrasound images and clinical data to diagnose pancreatic solid lesions. this study aims to improve the joint-ai model's performance with a prospectively collected dataset and validate it through a randomized controlled clinical trial.

Eligibility criteria:
inclusion criteria: * imaging examinations (mri, ct, b-ultrasound) show a solid mass in the pancreas, which requires endoscopic ultrasound guided-fine needle aspiration/biopsy (eus-fna/b) to clarify the nature of the lesion in patients. * written consent provided exclusion criteria: * age under 18 years old

Keywords: pancreatic cancer artificial intelligence endoscopic ultrasound
the effects of sacroiliac joint dysfunction on gait and disability

Conditions: Chronic Low-back Pain; Sacroiliac Joint Dysfunction; Gait, Unsteady; Disability Physical

Summary: it has been reported that gait coordination changes in patients with chronic low back pain, walking slower, taking shorter steps and having asymmetrical stride lengths compared to their healthy peers. in addition to many factor cause gait dysfunction, sacroiliac joint dysfunction might be one of reason of these problems. a study examining the effects of sacroiliac joint dysfunction on gait and disability in individuals with chronic low back pain has not been found in the literature. therefore, the aim of this study is to evaluate the gait parameters and disability of individuals with chronic low back pain and to reveal their relationship with sacroiliac joint dysfunction.


Eligibility criteria:
inclusion criteria: * volunteered to participate in the study. * patients with 18-65 years * low back pain for at least 3 months, * reported pain severity of 2 or greater according to the numeric pain rating scale exclusion criteria: * previous spine or lower extremity surgery * pregnancy * severe hypermobility syndromes * severe osteoporosis * spondyloarthropathies * spondylolisthesis * systemic inflammatory diseases * any neurological disorder that affects balance and gait
effects of iron supplementation on pediatric vaccine response

Conditions: Iron-deficiency; Iron Deficiency Anemia; Vaccination; Pediatric ALL

Summary: id/ida affects many young children in africa. vaccines provide tremendous benefits in lmic; however, they currently fail to reach their full potential. we need to better understand the causes of vaccine failure, in order to develop new strategies to improve vaccine immunogenicity. this study will contribute to children's health by: (1) providing updated guidelines to better define the prevalence of id/ida in early infancy, and its safe and effective control using iron; and (2) providing a new approach to improve response to pediatric vaccines in lmic, by ensuring adequate iron status at time of vaccination.

two major pediatric public health goals in lmic are increasing immunization effectiveness and reducing id/ida in children. id/ida affects many young children in africa. current guidelines do not recommend routine testing of hemoglobin in early infancy, as it is generally believed that most infants are born with adequate iron stores to last 6 months. however, many african infants are born with low iron stores and id/ida may develop earlier than generally appreciated, within 2-3 months after birth. vaccines provide tremendous benefits in lmic; however, they currently fail to reach their full potential. we need to better understand the causes of vaccine failure, in order to develop new strategies to improve vaccine immunogenicity. despite lower efficacy in lmic, these vaccines provide a major benefit because the disease burden is so high; however, if approaches can be found to improve immunogenicity, these vaccines would be even more powerful. for this study, 6 weeks old infants will be randomly assigned to two study groups. group 1 will receive iron at time of pediatric vaccinations from age 6-24 weeks. group 2 will receive no iron at time of pediatric vaccinations. all infants will receive a multivitamin syrup from age 6-24 weeks. all infants remaining id/ida at age 24 weeks will receive iron. infants will be followed-up until age 52 weeks.

Eligibility criteria:
inclusion criteria: * mother at least ≥15 years of age. * 6 weeks (+/- 3 days) of age * iron deficient (erythrocyte zinc protoporphyrin (znpp) \>61 μmol/mol heme) * with or without anemia, but not severely anemic (hb \>70 g/l) * no malaria * no medical condition that precludes study involvement * mother hiv negative * vaginal delivery * no iron supplementation prior to study enrolment * not wasted (length for height z score of ≥-2) * not underweight (weight for age z score ≥-2) * from the hospital record, term or late preterm delivery (≥34 weeks) * full-time breastfed at least until the screening * no vaccines beyond the birth dose of opv and bcg prior to enrolment
a study of aleglitazar in patients with type 2 diabetes

Conditions: Diabetes Mellitus Type 2

Summary: this 6 arm study will assess the efficacy, safety, tolerability and pharmacokinetics of aleglitazar therapy in patients with type 2 diabetes. patients will be randomised to one of 6 treatment arms, to receive one of 4 doses of aleglitazar, actos as an open-label active comparator, or placebo. aleglitazar will be administered starting from a dose of 0.05mg po daily, and actos will be administered at a dose of 45mg once daily. the anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.


Eligibility criteria:
inclusion criteria: * adult patients, 18-75 years of age; * type 2 diabetes, diagnosed \>=1 month of screening; * either drug-naive, or pretreated with a maximum of 2 oral antihyperglycemic agents at submaximal doses; * hba1c \<=10.0% at screening, and 7.0-10.0% at pre-randomisation visit. exclusion criteria: * type 1 diabetes; * currently or previously treated with insulin, a thiazolidinedione, or a dual peroxisome proliferator activated receptor (ppar) agonist; * clinically significant cardiovascular disease; * congestive heart failure (chf) new york heart association (nyha) 3-4.
effect of pdrn in post-operative scars

Conditions: Scar

Summary: the investigators aimed to evaluate the efficacy of pdrn administration in early wound healing phase on prevention of post-operative scars after open thyroidectomy.


Eligibility criteria:
inclusion criteria: • participants who underwent open thyroidectomy between february 2019 and march 2021 at the thyroid cancer center, department of otorhinolaryngology, seoul national university bundang hospital exclusion criteria: * age younger than 20 years or older than 60 years * history of keloid development * requirement for modified radical neck dissection * previous neck surgery * current pregnancy or breast feeding * allergy to pdrn * taking medications that may affect inflammation and would healing such as isotretinoin, anti-cancer drugs, high dose corticosteroids, and anticoagulants * uncontrolled medical diseases
pilot trial of abdominal core rehabilitation to improve outcomes after ventral hernia repair

Conditions: Ventral Hernia; Hernia; Herniorrhaphy; Abdominal Wall; Postoperative Period; Physical Therapy Modalities

Summary: this study aims to evaluate the potential role of physical therapy in improving outcomes after ventral hernia repair.

after being informed about the study and potential risks, all patients giving written informed consent will perform assessments of several activities of daily living and complete several surveys detailing their pre-surgical abilities, quality of life, and pain. immediately after their surgical procedure, patients will be randomized in a single-blind manner (investigator) in a 1:1 ratio to supervised physical therapy (8 weeks, twice weekly) or standard post-surgical precautions. assessments and surveys will be repeated by the blinded investigator at 30 days, 10 weeks, 6 months, and 1 year after surgery.

Eligibility criteria:
inclusion criteria * ages 18+ * diagnosis of ventral hernia * scheduled for elective ventral hernia repair * independent functional status * transverse hernia width of 2cm or greater exclusion criteria * previously diagnosed movement or balance disorder * use of ambulatory assistive device (walker or cane) * not currently undergoing or planning to undergo physical therapy or other skilled exercise intervention supervised by a medical rehabilitation professional

Keywords: ventral hernia repair abdominal core health physical therapy